AbbVie settles New York opioid case for $200 million as trial winds down
By Brendan Pierson (Reuters) – AbbVie Inc agreed to pay $200 million to settle claims by New York that its Allergan unit helped fuel an epidemic of opioid addiction in the state, shortly before jurors heard closing arguments from remaining defendant Teva Pharmaceutical Industries Ltd in a trial that has lasted more than five months. …
AbbVie settles New York opioid case for $200 million as trial winds down Read More »